Xiaflex collagenase clostridium histolyticum regulatory update

EMA’s CHMP recommended expanding the label of Xiapex collagenase clostridium histolyticum from Swedish Orphan to include the treatment of Peyronie’s disease with a palpable plaque and curvature deformity of >=30 degrees. The injectable form of collagenase is approved in the EU to treat Dupuytren’s contracture in adult patients with a palpable cord, which affects joints in the hand. ...